Loading
NASDAQHealthcareBiotechnology
Latest quote
$9.1621
−$0.1979 · -2.11%
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Regular session
$9.1621
−$0.1979 · -2.11%
Regular session · ET · Market data may be delayed.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Day range
Current $9.1621
52-week range
Current $9.1621
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
55
Mixed
Risk
51
Elevated Risk
Momentum
92
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Day range
Current $9.1621
52-week range
Current $9.1621
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | 578K USD | 701K USD | 556K USD | 574K USD |
| Gross profit | −578K USD | −701K USD | −556K USD | −574K USD |
| Research and development | 137.77M USD | 67.82M USD | 49.12M USD | 26.57M USD |
| Selling, general, and administrative | 30.73M USD | 14.42M USD | 7.61M USD | 4.1M USD |
| Operating expenses | 168.51M USD | 82.25M USD | 56.73M USD | 30.67M USD |
| Interest income | 5.52M USD | 4.5M USD | 1.1M USD | 429K USD |
| Depreciation and amortization | 578K USD | 701K USD | 556K USD | 574K USD |
| Operating income | −169.08M USD | −82.95M USD | −57.28M USD | −31.25M USD |
| Net income | −161.15M USD | −77.58M USD | −55.71M USD | −30.02M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$29.20
218.70% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.16M0.00%2.3T USD0.03%$379.11-0.51%
iShares Russell 2000 ETFIWM3.07M0.00%78.56B USD0.19%$277.15-0.20%
Vanguard Extended Market ETFVXF2.82M0.00%95.4B USD0.05%$232.8-0.30%
iShares Russell 2000 Growth ETFIWO992.44K0.01%14.25B USD0.24%$352.61-0.78%
Schwab U.S. Small-Cap ETFSCHA870.05K0.00%21.7B USD0.03%$32.585-0.08%
Vanguard Russell 2000 ETFVTWO774.56K0.00%18B USD0.06%$111.94-0.25%
Fidelity Enhanced Small Cap ETFFESM575.26K0.01%6.41B USD0.28%$45.155-0.14%
Vanguard Health Care ETFVHT407.85K0.00%22B USD0.09%$313.54-0.56%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
